Clinical trials
Advanced Cancer clinical trials
Below are recruiting advanced cancer clinical trials, each written for real people, not researchers. We’re tracking 2,223 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07189871RecruitingPhase 1/Phase 2
177Lu-BetaBart for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-BetaBart, for people with certain advanced solid tumors that have stopped responding to other treatments. The goal is to see if it can shrink tumors or slow their growth.
Dothan, AlabamaAges 18 years+ - NCT06735391RecruitingPhase 3
JMT101 plus osimertinib vs osimertinib for EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
GuangzhouAges 18 years+ - NCT06218810RecruitingPhase 2
Combination therapy for advanced MSS, RAS-mutated colorectal cancer
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
ShanghaiAges 18–75 - NCT07197554RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
Duarte, CaliforniaAges 16 years+ - NCT06265025RecruitingPhase 1/Phase 2
GM103 injection for advanced solid tumors that can't be removed
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT05752552RecruitingPhase 1
Safety study of a MET-targeting pill for advanced lung cancer
This Phase 1 trial tests DO-2 to see how safe it is and how the body absorbs it (pharmacokinetics) in people with advanced or metastatic lung cancer. It is for tumors that have a specific MET exon 14 “skipping” mutation and for whom standard treatments are no longer an option.
BrusselsAges 18 years+ - NCT07028489Recruiting
Studying a standard-care comparison group for advanced EGFR-mutant lung cancer
This trial collects information from people with a specific type of advanced lung cancer to create a comparison group. It helps researchers understand how well new treatments work without giving any experimental medicine.
Monterey, CaliforniaAges 18 years+ - NCT05327010RecruitingPhase 2
Testing a new drug combination for advanced solid tumors
This trial is studying whether a new combination of two cancer drugs, ZEN003694 and talazoparib, can help people with advanced solid tumors that have not responded to other treatments. Talazoparib is a type of drug that targets cancer cells with certain DNA repair problems. The study is divided into groups based on specific gene mutations or previous treatment responses.
Duarte, CaliforniaAges 18 years+ - NCT07197580RecruitingPhase 3
Study of a targeted radiation therapy for advanced kidney cancer
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
Sydney, New South WalesAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT07435454RecruitingPhase 2
Oral paclitaxel plus radiation for advanced esophageal cancer
This trial tests a combination of an oral chemotherapy drug (paclitaxel) and radiation therapy for people with advanced esophageal cancer that cannot be removed by surgery. It may be an option if you are 70 or older or cannot tolerate IV chemotherapy and have trouble swallowing.
Nanjing, JiangsuAges 70 years+ - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65 - NCT06295159RecruitingPhase 2
Immunotherapy before and after surgery for advanced melanoma
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
Tampa, FloridaAges 18 years+ - NCT06911333RecruitingPhase 1/Phase 2
A new drug for advanced solid tumors that have stopped responding to treatment
This trial tests a new drug called AD1208 for people with advanced solid tumors that have grown despite previous treatments. The goal is to see if the drug can help where other options no longer work or are not suitable.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06418412Recruiting
Pan-Asian study for EGFR exon 20 insertion lung cancer
This trial is building a large database of lung cancer patients from Asia who have a specific EGFR mutation (exon 20 insertion). Your medical records and treatment information will be collected to help doctors learn more about this type of cancer and improve care.
SingaporeAges 21–99 - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT07374692Recruiting
Study of treatments for advanced brain and spinal cord tumors
This study looks at how different treatments work for people with advanced brain or spinal cord tumors that have come back. It helps doctors learn more about these tumors and how to better treat them.
Bethesda, MarylandAges 15–120 - NCT04771520RecruitingPhase 2
Avapritinib for tumors with specific KIT or PDGFRA changes
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
Houston, TexasAges 18 years+ - NCT06438588Recruiting
Fasting-mimicking diet to reduce immunotherapy side effects
This trial tests whether a special low-calorie 'fasting-mimicking' diet can reduce side effects from common immunotherapy drugs for advanced cancer. If you're on a PD-1, PD-L1, or CTLA-4 inhibitor, this diet might help you feel better during treatment.
Jacksonville, FloridaAges 18 years+ - NCT06092086RecruitingPhase 2
Lorlatinib for first-line treatment of ALK-positive lung cancer
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Guangzhou, GuangdongAges 18 years+ - NCT07638891RecruitingPhase 1
HDM2020 for Advanced Squamous Lung Cancer
This study tests a new drug called HDM2020 in patients with advanced squamous cell lung cancer (a specific type of lung cancer) that has stopped responding to standard treatments. The drug is designed to target cancer cells that have high levels of a specific protein called FGFR2b.
Guangzhou, GuangdongAges 18–75 - NCT06509490Recruiting
CAR-T cell therapy for advanced NKG2DL-positive solid tumors
This trial tests a new type of immune cell therapy (NKG2D CAR-T cells) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if these specially engineered cells can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–70 - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Glendale, ArizonaAges 18 years+
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced cancer?
- Yes. Clin2 currently lists 2,223 recruiting advanced cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.